NO800475L - Befruktningshindrende middel for bruk i forbindelse med en intrauterin anordning - Google Patents
Befruktningshindrende middel for bruk i forbindelse med en intrauterin anordningInfo
- Publication number
- NO800475L NO800475L NO800475A NO800475A NO800475L NO 800475 L NO800475 L NO 800475L NO 800475 A NO800475 A NO 800475A NO 800475 A NO800475 A NO 800475A NO 800475 L NO800475 L NO 800475L
- Authority
- NO
- Norway
- Prior art keywords
- aromatic
- guanidine
- drug
- group
- class consisting
- Prior art date
Links
- 230000004720 fertilization Effects 0.000 title claims description 7
- 230000002265 prevention Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims description 89
- 229940079593 drug Drugs 0.000 claims description 85
- 125000003118 aryl group Chemical group 0.000 claims description 83
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 61
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 28
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 26
- 210000004291 uterus Anatomy 0.000 claims description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 23
- 150000001409 amidines Chemical class 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- 230000001567 anti-fibrinolytic effect Effects 0.000 claims description 12
- 230000000636 anti-proteolytic effect Effects 0.000 claims description 12
- 150000002357 guanidines Chemical class 0.000 claims description 12
- 206010027514 Metrorrhagia Diseases 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 208000007106 menorrhagia Diseases 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- PKSBDZOBYIKNGY-UHFFFAOYSA-N (4-nitrophenyl) 4-(diaminomethylideneamino)benzoate;hydrochloride Chemical compound Cl.C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 PKSBDZOBYIKNGY-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000003433 contraceptive agent Substances 0.000 claims description 4
- 229940082620 antifibrinolytics Drugs 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000000504 antifibrinolytic agent Substances 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 239000001294 propane Substances 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 5
- 239000000654 additive Substances 0.000 claims 4
- 230000000996 additive effect Effects 0.000 claims 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 206010033372 Pain and discomfort Diseases 0.000 claims 1
- XREMJLYGBPJHOQ-UHFFFAOYSA-N [Cl-].NC=1C=C(C=CC=1)C=1[N+](=C2C=C(C(=C(C2=C2C=CC=CC=12)N=[N+]=[N-])C1=CC=CC=C1)N)CC Chemical compound [Cl-].NC=1C=C(C=CC=1)C=1[N+](=C2C=C(C(=C(C2=C2C=CC=CC=12)N=[N+]=[N-])C1=CC=CC=C1)N)CC XREMJLYGBPJHOQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 12
- 210000004696 endometrium Anatomy 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 8
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 7
- 229960002684 aminocaproic acid Drugs 0.000 description 7
- 230000003509 anti-fertility effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- -1 aromatic amidines Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000002254 contraceptive effect Effects 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- GMJFVGRUYJHMCO-UHFFFAOYSA-N dibrompropamidine Chemical compound BrC1=CC(C(=N)N)=CC=C1OCCCOC1=CC=C(C(N)=N)C=C1Br GMJFVGRUYJHMCO-UHFFFAOYSA-N 0.000 description 6
- 229960000493 dibrompropamidine Drugs 0.000 description 6
- 230000002357 endometrial effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 4
- 239000004621 biodegradable polymer Substances 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 4
- 229960000401 tranexamic acid Drugs 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000320 amidine group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 101800004538 Bradykinin Proteins 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- 108090000113 Plasma Kallikrein Proteins 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 201000003511 ectopic pregnancy Diseases 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- DNOSZYUZVCJLMM-UHFFFAOYSA-N carbamimidoylazanium;benzoate Chemical compound NC(N)=[NH2+].[O-]C(=O)C1=CC=CC=C1 DNOSZYUZVCJLMM-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicinal Preparation (AREA)
- Catching Or Destruction (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5590379A | 1979-07-09 | 1979-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO800475L true NO800475L (no) | 1981-01-12 |
Family
ID=22000920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO800475A NO800475L (no) | 1979-07-09 | 1980-02-21 | Befruktningshindrende middel for bruk i forbindelse med en intrauterin anordning |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0024779B1 (de) |
| JP (1) | JPS5612314A (de) |
| AU (1) | AU538963B2 (de) |
| CH (1) | CH645538A5 (de) |
| DE (1) | DE3069441D1 (de) |
| NO (1) | NO800475L (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57181371A (en) * | 1981-04-28 | 1982-11-08 | Kawasaki Steel Corp | Production of zinc hot dipped steel plate by minimum spangle treatment |
| JPS5920456A (ja) * | 1982-07-21 | 1984-02-02 | Sumitomo Metal Ind Ltd | プレコ−ト鋼板の製造法 |
| JPS6014109A (ja) * | 1983-07-06 | 1985-01-24 | Kawasaki Steel Corp | めつき鋼板のめつき付着量測定装置 |
| GB8327561D0 (en) * | 1983-10-14 | 1983-11-16 | Ici Plc | Contraceptive methods |
| JPS6075456U (ja) * | 1983-10-26 | 1985-05-27 | 新日本製鐵株式会社 | メツキ鋼帯の合金化炉 |
| JPS61145439A (ja) * | 1984-12-19 | 1986-07-03 | Kawasaki Steel Corp | 合金化溶融亜鉛めつき鋼板の合金化度測定方法 |
| NL8600250A (nl) * | 1986-02-01 | 1987-09-01 | Fundatech Sa | Vaginaal anticonceptiemiddel. |
| MX16687A (es) * | 1988-07-07 | 1994-01-31 | Ciba Geigy Ag | Compuestos de biarilo y procedimiento para su preparacion. |
| JPH02228459A (ja) * | 1989-03-01 | 1990-09-11 | Nippon Steel Corp | 合金層特性測定方法 |
| JP2708257B2 (ja) * | 1990-03-23 | 1998-02-04 | 新日本製鐵株式会社 | 合金化溶融亜鉛めっき鋼板の相厚の測定方法 |
| IN172842B (de) * | 1990-05-17 | 1993-12-11 | Boots Pharmaceuticals Limited | |
| EP0495749A1 (de) * | 1991-01-14 | 1992-07-22 | Ciba-Geigy Ag | Bipyridyle |
| EP2140860A1 (de) | 2008-07-03 | 2010-01-06 | Bayer Schering Pharma Oy | Verbessertes Verhütungsverfahren |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB376806A (en) * | 1931-04-07 | 1932-07-07 | William Hogan Lewers | Improvements in polymethylenediguanidine compounds and their process of manufacture |
| GB516289A (en) * | 1938-06-24 | 1939-12-29 | May & Baker Ltd | New therapeutically valuable diguanidine compounds |
| GB938042A (en) * | 1961-03-30 | 1963-09-25 | Wellcome Found | Phenoxyalkanes |
| BE789524A (fr) * | 1971-09-30 | 1973-01-15 | Alza Corp | Dispositif de liberation de medicaments |
| GB1503499A (en) * | 1974-08-23 | 1978-03-08 | Fisons Ltd | Antiprotozoal method and composition |
-
1979
- 1979-11-21 AU AU53070/79A patent/AU538963B2/en not_active Ceased
- 1979-11-28 JP JP15413179A patent/JPS5612314A/ja active Pending
- 1979-11-29 CH CH1062879A patent/CH645538A5/de not_active IP Right Cessation
-
1980
- 1980-01-29 EP EP80300257A patent/EP0024779B1/de not_active Expired
- 1980-01-29 DE DE8080300257T patent/DE3069441D1/de not_active Expired
- 1980-02-21 NO NO800475A patent/NO800475L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3069441D1 (en) | 1984-11-22 |
| AU5307079A (en) | 1981-01-15 |
| CH645538A5 (de) | 1984-10-15 |
| JPS5612314A (en) | 1981-02-06 |
| EP0024779B1 (de) | 1984-10-17 |
| AU538963B2 (en) | 1984-09-06 |
| EP0024779A1 (de) | 1981-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO800473L (no) | Intrauterin anordning. | |
| NO800474L (no) | Intrauterin anordning. | |
| NO800475L (no) | Befruktningshindrende middel for bruk i forbindelse med en intrauterin anordning | |
| CN105979975B (zh) | 医疗敷料 | |
| RU96102572A (ru) | Способ лечения преэклампсий и угрозы преждевременных родов композицией агента, способствующего сохранению беременности, и субстратом и/или донором синтазы окиси азота | |
| RU2003138075A (ru) | Удерживаемая в желудке система регулируемой доставки лекарственного средства | |
| AU2002350644B2 (en) | Vaginally administerd anti-dysrhythmic agents for treating pelvic pain and infertility | |
| US10456292B2 (en) | Compositions and methods relating to an occlusive polymer hydrogel | |
| Gibbs et al. | Use of an anti-fibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms | |
| Hart et al. | Withdrawal syndromes and the cessation of antihypertensive therapy | |
| RU2329829C2 (ru) | Перекись в низкой концентрации для лечения или профилактики вагинальных инфекций | |
| PE20001414A1 (es) | Procedimiento de preparacion de globulos que contienen 50% en peso o mas de una sustancia farmaceutica de hidrosolubilidad | |
| AU2002350644A1 (en) | Vaginally administerd anti-dysrhythmic agents for treating pelvic pain and infertility | |
| RU2004138807A (ru) | Новые сложные эфиры этоногестрела | |
| US6207696B1 (en) | Compositions and methods for the prophylaxis and treatment of dysmenorrhea, endometriosis, and pre-term labor, using histidine | |
| DECKER et al. | Arteriovenous fistulas of the female pelvis: a diagnostic problem | |
| Levy et al. | Selective blockade of the vasodepressor response to prostaglandin F2α in the anaesthetized rabbit | |
| Platt | Antibiotic prophylaxis in surgery | |
| US4476141A (en) | Use of N-(6 aminohexyl)-5-chloro-1-naphthalenesulfonamide, N-(6 aminohexyl)-5-chloro-2-naphthalenesulfonamide, and N-(6 aminohexyl)-5-bromo-2-naphthalenesulfonamide as vaginal contraceptives | |
| AU2014252196B2 (en) | Progesteron receptor modulators for use in the therapy of uterine fibroids | |
| US4444789A (en) | Use of 8-anilino-1-naphthalenesulfonate as a vaginal contraceptive | |
| US20080182841A1 (en) | Vaginally administered anti-dysrhythmic agents for treating pelvic pain | |
| CN1703205B (zh) | 利用荷电聚合物的长效控释药物组合物 | |
| US4470996A (en) | Use of N-phenyl-1-naphthylamine as a vaginal contraceptive | |
| CA2429624A1 (en) | Compositions for adhesion prevention |